RxDoctor Payments Data

Lauren Chriscoe

Adult Health · Southern Pines, NCNPI 1225412778

Payments from drug & device makers

$3,786in general payments, 2019–2025

Across 181 payments — averaging $20.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$807
  • Esperion Therapeutics, Inc.$375
  • Boehringer Ingelheim$360
  • AstraZeneca$337
  • Amgen$251
  • AbbVie$249
  • plus $1K from 25 others

What the payments were for

  • Food & beverage$3,786100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,786 in reported general payments places this provider in the 85th percentile of 614 adult health providers in North Carolina.

See all adult health providers in North Carolina

Medicare billing

Part B allowed, 2024
$76,336
Medicare patients
177
Services billed
3,261

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide87$93,503
JardianceEmpagliflozin85$91,642
EliquisApixaban101$89,672
TrulicityDulaglutide25$46,583
OzempicSemaglutide29$44,076
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$24,579
XareltoRivaroxaban26$22,700
Breo ElliptaFluticasone/Vilanterol37$15,246
TrintellixVortioxetine Hydrobromide12$8,339
Atorvastatin Calcium250$2,527
SynthroidLevothyroxine Sodium23$2,401
Omeprazole164$2,370
Levothyroxine Sodium205$2,175
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$2,063
Lisinopril197$1,836

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$185$140,087112 claims
Boehringer IngelheimJardiance$360$91,64285 claims
PfizerEliquis$113$89,672101 claims
Novo NordiskOzempic$807$44,07629 claims
GSKTrelegy Ellipta, Breo Ellipta$43$39,82666 claims
Johnson & JohnsonXarelto$108$22,70026 claims
AbbVieSynthroid$249$2,40123 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$21$2,175205 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 614 adult health providers in North Carolina.

Other adult health in Southern Pines

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →